Recent Updates — OKYO

OKYO Pharma Limited announced the enrollment of its first patients in the Phase 3 NEPTUNE pivotal clinical trial evaluating urcosimod for neuropathic corneal pain (NCP). The multicenter study, initiated at Toyos Clinic in Nashville by Dr. Melissa Toyos, will expand to sites across the U.S., Italy, Spain, and France. Patients receive four drops daily for 12 weeks, with the primary efficacy endpoint measuring changes in ocular pain via VAS scores. This milestone advances clinical evidence for urcosimod as a potential first-in-class treatment for an unmet medical need. OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases.

On July 28, 2026, Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma, purchased 3,363 ordinary shares on NASDAQ at $1.49 per share, increasing his total holdings to 20,030 shares. OKYO Pharma is a clinical-stage biopharmaceutical company developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases.

OKYO Pharma Ltd announced its participation in the virtual BTIG Biotechnology Conference 2026 scheduled for July 28-29, 2026. Management representatives attending include CEO Robert J. Dempsey, CFO Keeren Shah, and CMO Flavio Mantelli. The company plans to initiate a global Phase 3 pivotal clinical trial in the second half of 2026, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain (NCP). OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases.